All News
#OP0004 #EULAR2022 In line with EULAR President’s preech to go Digital, Prof Mosca highlighted a study which showed assessment of joints in RA could be done by taking photos and analysed their dorsal skin folds using convolutional neural network @RheumNow https://t.co/h03mieTcQt
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Post-ORAL Surveillance, the @eular_org RA treatment guidelines had to change.
In the 2022 version:
JAKi now separate sentence following bDMARDs, with proviso to mention risk.
Sometimes guidelines have to tell us what we’ve all inevitably been expecting
#EULAR2022 @RheumNow https://t.co/RPbPNi3vcW
David Liew drdavidliew ( View Tweet)
#EULAR2022 POS0285
130K UK patients had incident gout bw 2004-2020
⭐️Only 29% started on ULT w/in 12 mos
⭐️Target urate level only 14% in 2004, only to 17% in 2020
Updated EULAR guidelines in 2016: No statistical difference in ULT Rx or target attainment
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA.
@RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
Robert B Chao, MD doctorRBC ( View Tweet)
RheumNow’s coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Rituximab/belimumab patients & COVID vaccination response:
may have had average antibody response
but there’s still the cellular response to consider too! Not as bad.
Still caution++, but when ritux really needed we’ll find a way despite COVID
from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG
David Liew drdavidliew ( View Tweet)
#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings.
Existing MRI scoring may underserve axSpA in women.
Added to therapy differences, a lot to readdress for our female axSpA patients.
from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM
David Liew drdavidliew ( View Tweet)
#highlight n•1 💫
The presence of specific peripheral blood T cell sub-populations associated w/ disease flares
in RA pts in remission after cs or bioDMARDs tapering or cessation
identified in 2 different abstracts
OP0011 and OP0074
@RheumNow #EULAR2022 https://t.co/SO2AgtkyTP
Aurelie Najm AurelieRheumo ( View Tweet)
Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity.
So much more to digest....
@RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 POS0282
Febuxostat vs allopurinol: CV risk population study
⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction
⭐️CV safety non-inferior to allopurinol
@Rheumnow https://t.co/1oDSioQWPT
Eric Dein ericdeinmd ( View Tweet)
Stimakovits et al. Influence of placebo vs active comparator in RA clinical trials. ACR response rates systematically higher in studies with active comparators. ACR20 OR 1.64 (1.44-1.86), ACR50 OR 1.46 (1.28-1.71), ACR70 OR 1.61 (1.28-2.02) @RheumNow #EULAR2022 POS0563 https://t.co/x7PQH11oue
Richard Conway RichardPAConway ( View Tweet)
We’re in the #EULAR2022 highlights: basic/translational first. Wait, don’t go…
because Temra cells are cool. Up in RA pts who are TNFi-IR, & may actually be more than a bystander.
Understanding TNFi resistance is path to:
predicting it
knowing best what to do with it
@RheumNow https://t.co/22Y6iinSbH
David Liew drdavidliew ( View Tweet)
Psoriasis and Psoriatic arthritis patients have different circulating microRNA signatures compared to healthy controls.
(miRNAs: non-coding RNAs controlling gene expression)
PsO/PsA miRNAs involved in bone metabolism
@RheumNow #EULAR2022 ABST#POS0314
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 POS0283: Do Rheums have Gout Stigma?
⭐️Stereotypes about pt related factors
⭐️Rheumatologists feel diet, exercise, wt loss more important in gout than RA, pharmacologic therapies less important than RA
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L
Links:
Richard Conway RichardPAConway ( View Tweet)
PMR on the podium @profbdasgupta, with a positive phase 3!
Sarilumab in relapsing PMR (SAPHYR):
sari q2w+14w taper vs placebo+52w taper
underrecruited 118/280 (COVID) but still hit primary, almost all secondary
Better outcome + steroid-sparing: big
LB0006 #EULAR2022 @RheumNow https://t.co/nd3TSibYa0
David Liew drdavidliew ( View Tweet)
#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts.
Note 100% fatigue resolution roughly same vs. placebo
@RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 LB0005
Orelabrutinib- BTKi- for SLE, PIb/IIa
⭐️Improved SRI-4 and SLEDAI-2K vs PBO, dose response for SRI-4
⭐️Improved proteinuria
@Rheumnow https://t.co/bmREhmL7sq
Eric Dein ericdeinmd ( View Tweet)